Zamto-cel cell therapy for autoimmune diseases
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of lupus (with or without kidney inflammation) or a type of systemic sclerosis called diffuse cutaneous systemic sclerosis.
- Your lupus must be active—measured by certain blood tests, disease activity scores, or organ involvement. For lupus with kidney disease, a recent kidney biopsy must show active inflammation.
- You must have tried and not responded well to at least two standard treatments (used for 3 months each), like steroids, hydroxychloroquine, or other immune-suppressing medications.
- If you have systemic sclerosis, your skin thickening score (mRSS) must be 16 or higher, or your lung disease must have worsened despite treatment.
- You cannot have had previous gene therapy, an active cancer in the last 5 years, a serious infection, or severe kidney or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.